Latest Headlines
-
BioNTech And DualityBio Receive FDA Fast Track Designation For Antibody-Drug Conjugate Candidate BNT324/DB-1311 In Prostate Cancer
6/24/2024
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer (“CRPC”) who have progressed on or after standard systemic regimens.
-
UCF Scientist Using AI To Speed Up Tuberculosis Drug Discovery
6/24/2024
As scientists harness artificial intelligence (AI) to accelerate drug discovery, UCF College of Medicine tuberculosis researcher Kyle Rohde has partnered with biotech company Atomwise to see how AI can speed up testing of potential drugs to treat the disease.
-
Novel Synthesis Of Fluorinated Molecules With Potential In Drug Research Developed
6/21/2024
Carboxylic acids are one of the most important substance classes in chemistry and are a component of many drugs such as aspirin and ibuprofen.
-
Transforming Drug Discovery With AI
6/21/2024
Michigan State University researchers have led the development of a new artificial intelligence (AI) program that can help speed up and reduce the cost of drug development
-
Membrane Protein Analogues Could Accelerate Drug Discovery
6/21/2024
EPFL researchers have created a deep learning pipeline for designing soluble analogues of key protein structures used in pharmaceutical development, sidestepping the prohibitive cost of extracting these proteins from cell membranes.
-
C-Path And CENTOGENE MOU To Enhance Collaboration In Lysosomal Disease Research And Drug Development
6/20/2024
Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and improve the quality of life for those impacted by these conditions.
-
Macomics And The Institute Of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration In Prostate Cancer Drug Development
6/19/2024
Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof. Andrea Alimonti at IOR (Institute of Oncology Research), one of Switzerland’s leading research institutes.
-
Transforming Inexpensive Quinolines Into Complex Drug Candidates
6/19/2024
An innovative synthesis strategy opened up the way to 2D/3D fused frameworks using inexpensive quinolines as feedstock, report scientists from Tokyo Tech.
-
Old Drugs New Tricks – Novel Approach Shows 'Enormous Potential' For Rapid Antibiotic Discovery
6/19/2024
An innovative project to re-purpose existing drugs for their potential as antibiotics has uncovered a highly promising candidate with a potent and unique way of killing drug resistant bacteria.
-
Researchers Uncover Enzyme Communication Mechanism That Could Aid Drug Development
6/18/2024
A mechanism that could help scientists harness enzymes for use in drug discovery has been discovered by researchers at the University of Birmingham.